Brief Report: Pilot Single-Blind Placebo Lead-In Study of Acamprosate in Youth with Autistic Disorder / Craig ERICKSON in Journal of Autism and Developmental Disorders, 44-4 (April 2014)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 44-4 (April 2014) . - p.981-987 Titre : Brief Report: Pilot Single-Blind Placebo Lead-In Study of Acamprosate in Youth with Autistic Disorder Type de document : texte imprimé Auteurs : Craig ERICKSON, Auteur ; Logan K. WINK, Auteur ; Maureen C. EARLY, Auteur ; Elizabeth STIEGELMEYER, Auteur ; Lauren MATHIEU-FRASIER, Auteur ; Vanessa PATRICK, Auteur ; Christopher J. MCDOUGLE, Auteur Année de publication : 2014 Article en page(s) : p.981-987 Langues : Anglais (eng) Mots-clés : Acamprosate  Autism spectrum disorder  Glutamate  Gamma-aminobutyric acid Index. décimale : PER Périodiques Résumé : An excitatory/inhibitory (E:I) imbalance marked by enhanced glutamate and deficient gamma-aminobutyric acid (GABA) neurotransmission may contribute to the pathophysiology of autism spectrum disorders (ASD). We report on the first single-blind placebo lead-in trial of acamprosate, a drug with putative mechanisms restoring E:I imbalance, in twelve youth with ASD. We conducted a 12-week single-blind, placebo lead-in study of acamprosate in youth age 5–17 years with autistic disorder. Six of nine subjects who received active drug treatment were deemed treatment responders (defined by a score at final visit of “very much improved” or “much improved” on the Clinical Global Impressions Improvement scale) and ≥25 % improvement on the Aberrant Behavior Checklist Social Withdrawal subscale. Future larger-scale dose finding studies of acamprosate in ASD may be warranted given this preliminary indication of benefit. En ligne : http://dx.doi.org/10.1007/s10803-013-1943-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=228 [article] Brief Report: Pilot Single-Blind Placebo Lead-In Study of Acamprosate in Youth with Autistic Disorder [texte imprimé] / Craig ERICKSON, Auteur ; Logan K. WINK, Auteur ; Maureen C. EARLY, Auteur ; Elizabeth STIEGELMEYER, Auteur ; Lauren MATHIEU-FRASIER, Auteur ; Vanessa PATRICK, Auteur ; Christopher J. MCDOUGLE, Auteur . - 2014 . - p.981-987. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 44-4 (April 2014) . - p.981-987 Mots-clés : Acamprosate  Autism spectrum disorder  Glutamate  Gamma-aminobutyric acid Index. décimale : PER Périodiques Résumé : An excitatory/inhibitory (E:I) imbalance marked by enhanced glutamate and deficient gamma-aminobutyric acid (GABA) neurotransmission may contribute to the pathophysiology of autism spectrum disorders (ASD). We report on the first single-blind placebo lead-in trial of acamprosate, a drug with putative mechanisms restoring E:I imbalance, in twelve youth with ASD. We conducted a 12-week single-blind, placebo lead-in study of acamprosate in youth age 5–17 years with autistic disorder. Six of nine subjects who received active drug treatment were deemed treatment responders (defined by a score at final visit of “very much improved” or “much improved” on the Clinical Global Impressions Improvement scale) and ≥25 % improvement on the Aberrant Behavior Checklist Social Withdrawal subscale. Future larger-scale dose finding studies of acamprosate in ASD may be warranted given this preliminary indication of benefit. En ligne : http://dx.doi.org/10.1007/s10803-013-1943-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=228

Case Report: 16-Year-Old Male with Autistic Disorder with Preoccupation with Female Feet / Maureen C. EARLY in Journal of Autism and Developmental Disorders, 42-6 (June 2012)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 42-6 (June 2012) . - p.1133-1137 Titre : Case Report: 16-Year-Old Male with Autistic Disorder with Preoccupation with Female Feet Type de document : texte imprimé Auteurs : Maureen C. EARLY, Auteur ; Craig ERICKSON, Auteur ; Logan K. WINK, Auteur ; Christopher J. MCDOUGLE, Auteur ; Eric L. SCOTT, Auteur Année de publication : 2012 Article en page(s) : p.1133-1137 Langues : Anglais (eng) Mots-clés : Autism  Female feet  Preoccupation  Exposure therapy  Differential diagnosis  CY-BOCS-PDD Index. décimale : PER Périodiques Résumé : This paper highlights clinical challenges faced when diagnosing and then treating an individual presenting to a child and adolescent psychiatry clinic because of unwelcome comments he made to female peers about their feet. Novel use of exposure therapy helped him effectively decrease his comments from 1 to 2 times per month to once every 6 months. Conceptualizing this case as the individual’s failed attempts toward relationships with females instead of sexual harassment led to diminution of problematic behavior. Implications for diagnosis and treatment of individuals with Autistic Disorder displaying problematic behaviors are presented. En ligne : http://dx.doi.org/10.1007/s10803-011-1340-8 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=156 [article] Case Report: 16-Year-Old Male with Autistic Disorder with Preoccupation with Female Feet [texte imprimé] / Maureen C. EARLY, Auteur ; Craig ERICKSON, Auteur ; Logan K. WINK, Auteur ; Christopher J. MCDOUGLE, Auteur ; Eric L. SCOTT, Auteur . - 2012 . - p.1133-1137. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 42-6 (June 2012) . - p.1133-1137 Mots-clés : Autism  Female feet  Preoccupation  Exposure therapy  Differential diagnosis  CY-BOCS-PDD Index. décimale : PER Périodiques Résumé : This paper highlights clinical challenges faced when diagnosing and then treating an individual presenting to a child and adolescent psychiatry clinic because of unwelcome comments he made to female peers about their feet. Novel use of exposure therapy helped him effectively decrease his comments from 1 to 2 times per month to once every 6 months. Conceptualizing this case as the individual’s failed attempts toward relationships with females instead of sexual harassment led to diminution of problematic behavior. Implications for diagnosis and treatment of individuals with Autistic Disorder displaying problematic behaviors are presented. En ligne : http://dx.doi.org/10.1007/s10803-011-1340-8 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=156

Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: A chart review study / Benjamin A. ADLER in Autism, 19-1 (January 2015)  

Public ISBD [article]  inAutism > 19-1 (January 2015) . - p.102-106 Titre : Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: A chart review study Type de document : texte imprimé Auteurs : Benjamin A. ADLER, Auteur ; Logan K. WINK, Auteur ; Maureen C. EARLY, Auteur ; Rebecca SHAFFER, Auteur ; Noha F. MINSHAWI, Auteur ; Christopher J. MCDOUGLE, Auteur ; Craig ERICKSON, Auteur Article en page(s) : p.102-106 Langues : Anglais (eng) Mots-clés : aggression  atypical antipsychotics  autism  autism spectrum disorders  self-injurious behavior  severe tantrums Index. décimale : PER Périodiques Résumé : Aggression, self-injurious behavior, and severe tantrums are impairing symptoms frequently experienced by individuals with autism spectrum disorders. Despite US Food and Drug Administration approval of two atypical antipsychotics targeting these symptoms in youth with autistic disorder, they remain frequently drug refractory. We define drug-refractory aggression, self-injurious behavior, and severe tantrums in people with autism spectrum disorders as behavioral symptoms requiring medication adjustment despite previous trials of risperidone and aripiprazole or previous trials of three psychotropic drugs targeting the symptom cluster, one of which was risperidone or aripiprazole. We reviewed the medical records of individuals of all ages referred to our clinic for autism spectrum disorder diagnostic evaluation, as well as pharmacotherapy follow-up notes for all people meeting autism spectrum disorder criteria, for drug-refractory symptoms. Among 250 consecutively referred individuals, 135 met autism spectrum disorder and enrollment criteria, and 53 of these individuals met drug-refractory symptom criteria. Factors associated with drug-refractory symptoms included age 12 years or older (p < 0.0001), diagnosis of autistic disorder (p = 0.0139), and presence of intellectual disability (p = 0.0273). This pilot report underscores the significance of drug-refractory aggression, self-injurious behavior, and severe tantrums; suggests the need for future study clarifying factors related to symptom development; and identifies the need for focused treatment study of this impairing symptom domain. En ligne : http://dx.doi.org/10.1177/1362361314524641 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=245 [article] Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: A chart review study [texte imprimé] / Benjamin A. ADLER, Auteur ; Logan K. WINK, Auteur ; Maureen C. EARLY, Auteur ; Rebecca SHAFFER, Auteur ; Noha F. MINSHAWI, Auteur ; Christopher J. MCDOUGLE, Auteur ; Craig ERICKSON, Auteur . - p.102-106. Langues : Anglais (eng) in Autism > 19-1 (January 2015) . - p.102-106 Mots-clés : aggression  atypical antipsychotics  autism  autism spectrum disorders  self-injurious behavior  severe tantrums Index. décimale : PER Périodiques Résumé : Aggression, self-injurious behavior, and severe tantrums are impairing symptoms frequently experienced by individuals with autism spectrum disorders. Despite US Food and Drug Administration approval of two atypical antipsychotics targeting these symptoms in youth with autistic disorder, they remain frequently drug refractory. We define drug-refractory aggression, self-injurious behavior, and severe tantrums in people with autism spectrum disorders as behavioral symptoms requiring medication adjustment despite previous trials of risperidone and aripiprazole or previous trials of three psychotropic drugs targeting the symptom cluster, one of which was risperidone or aripiprazole. We reviewed the medical records of individuals of all ages referred to our clinic for autism spectrum disorder diagnostic evaluation, as well as pharmacotherapy follow-up notes for all people meeting autism spectrum disorder criteria, for drug-refractory symptoms. Among 250 consecutively referred individuals, 135 met autism spectrum disorder and enrollment criteria, and 53 of these individuals met drug-refractory symptom criteria. Factors associated with drug-refractory symptoms included age 12 years or older (p < 0.0001), diagnosis of autistic disorder (p = 0.0139), and presence of intellectual disability (p = 0.0273). This pilot report underscores the significance of drug-refractory aggression, self-injurious behavior, and severe tantrums; suggests the need for future study clarifying factors related to symptom development; and identifies the need for focused treatment study of this impairing symptom domain. En ligne : http://dx.doi.org/10.1177/1362361314524641 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=245

---

1 (1 - 3 / 3) Par page : 25 50 100 200